Testosterone undecanoate and testosterone enanthate injections are both effective and safe in transmen over 5 years of administration
- 19 July 2018
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 89 (6) , 878-886
Abstract
Summary: Objective: To retrospectively evaluate and compare safety and efficacy of short and long‐acting testosterone (T) parenteral formulations over 5 years in transmen.Design and methods: Fifty transmen between 21 and 42 years of age were enrolled. Twenty‐five received T undecanoate 1000 mg IM (weeks 0 and 6 then every 12‐16 weeks), and 25 received T enanthate 250 mg IM (every 3‐4 weeks). Hormonal and biochemical parameters, anthropometric characteristics and blood pressure were assessed at baseline and then every 12 months. Body composition was evaluated at baseline and then after 1, 3 and 5 years of T treatment. Global satisfaction was assessed at baseline and after 1 and 5 years.Results: Both T formulations led to amenorrhoea in all subjects within 1 year of T administration. Both T treatments led to a similar increase in haemoglobin and haematocrit which always remained within the physiological range. T administration was associated with an increase in total cholesterol, low‐density lipoprotein cholesterol and triglycerides and a slight reduction in high‐density lipoprotein cholesterol. Coagulative and glucidic profiles and blood pressure did not change significantly in either group. Body weight and BMI showed a slight but not significant increase in both groups, while lean mass rose significantly in both groups. Global satisfaction was increased at years 1 and 5 in both groups.Conclusions: Preliminary results from this pilot study suggest that administration of either TU or TE for 5 years in young transmen is both effective and safe. Our study presents the longest follow‐up published so far reporting no adverse events and these data are consistent with previous reports with a shorter follow‐up.Keywords
This publication has 43 references indexed in Scilit:
- Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7International Journal of Transgenderism, 2012
- The validation of the visual analogue scale for patient satisfaction after total hip arthroplastyEuropean Orthopaedics and Traumatology, 2012
- A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormonesEuropean Journal of Endocrinology, 2011
- The impact of testosterone administration to female-to-male transsexuals on insulin resistance and lipid parameters compared with women with polycystic ovary syndromeFertility and Sterility, 2010
- Testosterone Suppresses Hepcidin in Men: A Potential Mechanism for Testosterone-Induced ErythrocytosisThe Journal of Clinical Endocrinology & Metabolism, 2010
- Effects of Intramuscular Testosterone Undecanoate on Body Composition and Bone Mineral Density in Female-to-Male TranssexualsThe Journal of Sexual Medicine, 2010
- Alterations in Lipids and Adipocyte Hormones in Female-to-Male TranssexualsInternational Journal of Endocrinology, 2010
- Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individualsEuropean Journal of Endocrinology, 2009
- Effects of Testosterone Undecanoate Administered Alone or in Combination with Letrozole or Dutasteride in Female to Male TranssexualsThe Journal of Sexual Medicine, 2008
- Long-Term Testosterone Administration Increases Visceral Fat in Female to Male TranssexualsThe Journal of Clinical Endocrinology & Metabolism, 1997